• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Meta-Analysis of Gender Differences in Residual Stroke Risk and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants
In conclusion, women with AF treated with warfarin have a greater residual risk of CVA/SE and an equivalent major bleeding risk, whereas those treated with NOAC agents deemed superior to warfarin are at equivalent residual risk of CVA/SE and less major bleeding risk compared with men. These results suggest an increased net clinical benefit of NOAC agents compared with warfarin in treating women with AF.
Source: The American Journal of Cardiology - November 14, 2013 Category: Cardiology Authors: Samir B. Pancholy, Parikshit S. Sharma, Dipti S. Pancholy, Tejas M. Patel, David J. Callans, Francis E. Marchlinski Tags: Arrhythmias and Conduction Disturbances Source Type: research

Effect of Dabigatran on Referrals to and Switching From Warfarin in Two Academic Anticoagulation Management Services
Dabigatran was expected to replace warfarin for stroke prevention in patients with nonvalvular atrial fibrillation (AF) who are warfarin naive, difficult to maintain in therapeutic range, or at risk of warfarin-related bleeding complications. We hypothesized that the number of patients with nonvalvular AF referred to Anticoagulation Management Services would decrease sharply and that most would switch from warfarin to dabigatran. We evaluated the number of patients with nonvalvular AF referred to 2 large services, Anticoagulation Management Service 1 and Anticoagulation Management Service 2, 12 months before and after mark...
Source: The American Journal of Cardiology - May 6, 2013 Category: Cardiology Authors: Julie K. Atay, John Fanikos, Geoffrey D. Barnes, Michael Ehle, John Coatney, Gregory Piazza, James B. Froehlich, Samuel Z. Goldhaber Tags: Arrhythmias and Conduction Disturbances Source Type: research

Safety of Continuous Anticoagulation With Dabigatran During Implantation of Cardiac Rhythm Devices
In conclusion, although no thromboembolic or major bleeding events were observed, additional studies are required to define the optimal antithrombotic management in the perioperative period.
Source: The American Journal of Cardiology - January 28, 2013 Category: Cardiology Authors: Christopher P. Rowley, Michael L. Bernard, William W. Brabham, Peter C. Netzler, Darren S. Sidney, Frank Cuoco, J. Lacy Sturdivant, Robert B. Leman, J. Marcus Wharton, Michael R. Gold Tags: Arrhythmias and Conduction Disturbances Source Type: research

Pages: 1  2  3